Ariad Pharma (ARIA) Misses Q4 EPS, Revenue Expectations

Ariad Pharma (NASDAQ: ARIA) reported Q4 EPS of ($0.38), $0.19 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $78 thousand versus the consensus estimate of $940 thousand.

For earnings history and earnings-related data on Ariad Pharma (ARIA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Why Michael Burry says Berkshire is no longer attractive under Abel
• Adamas Trust prices $90M senior notes offering at 9.600%